Combinatorial immunotherapy strategies: most gods throw dice, but fate
Résumé
Immuno-oncology drugs (IODs) are considered as game-changing treatments in oncology, because diseases with once dismal prognosis such as metastatic melanoma or lung cancer now show 3-year survival rates in the 20-40% range. However, it has to be kept in mind
Origine | Fichiers produits par l'(les) auteur(s) |
---|